Inhibition of P21-activated kinases 1 and 4 synergistically suppress the growth of pancreatic cancer by stimulating anti-tumour immunity

Author:

Ma Yi1,Dumesny Chelsea1,Dong Li1,Ang Ching-Seng1,Asadi Khashayar2,Zhan Yifan3,Nikfarjam Mehrdad1,He Hong1

Affiliation:

1. University of Melbourne

2. Austin Health

3. Shanghai Huaota Biopharm

Abstract

Abstract Background: Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal types of cancer, and KRAS oncogene occurs in over 90% of cases. P21-activated kinases (PAK), containing six members (PAK1 to 6), function downstream of KRAS. PAK1 and PAK4 play important roles in carcinogenesis, but their combinational effect remains unknown. In this study, we have determined the effect of dual inhibition of PAK1 and PAK4 in PDA progression using knockout (KO) cancer cell lines. Methods: Murine wild-type (WT) and PAK1KO pancreatic cancer cell lines were isolated from PAK1+/+ and PAK1-/- KPC (LSL-KrasG12D/+; LSL-Trp53 R172H/+; Pdx-1-Cre) mice. KPC PAK4KO and KPC PAK1&4 KO cell lines were generated from KPC WT and KPC PAK1KO cell lines respectively using the CRISPR-CAS9 gene knockout technique. PAK WT and KO cell lines were used in mouse models of pancreatic tumours. Cells and tumour tissue were also used in flow cytometry and proteomic studies. A human PDA tissue microarray was stained by immunohistochemistry. Results: Double knock out of PAK1 and PAK4 caused complete regression of tumour in a syngeneic mouse. PAK4KO inhibited tumour growth by stimulating a rapid increase of cytotoxic CD8+ T cell infiltration. PAK1KO synergistically with PAK4KO increased cytotoxic CD8+ T cell infiltration and stimulated a sustained infiltration of CD8+ T cells at a later phase to overcome the immune evasion in the PAK4KO tumour. The human PDA tissue microarray study showed the important role of PAK1 and PAK4 in intra-tumoral T-cell function. Conclusion: Our results demonstrated that dual inhibition of PAK1 and PAK4 synergistically suppressed PDA progression by stimulating cytotoxic CD8+ T cell response.

Publisher

Research Square Platform LLC

Reference34 articles.

1. AIHW. Cancer in Australia 2019. Cancer series. Canberra: Australian Institute of Health and Welfare; 2019.

2. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies;Adamska A;Int J Mol Sci,2017

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Hoff DD;N Engl J Med,2013

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy T;N Engl J Med,2011

5. A brain serine/threonine protein kinase activated by Cdc42 and Rac1;Manser E;Nature,1994

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3